RxDoctor Payments Data

Karly Baier, OD

Optometrist · Phoenix, AZNPI 1003330549

Payments from drug & device makers

$1,472in general payments, 2019–2025

Across 47 payments — averaging $31.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$396
  • Bausch & Lomb Americas Inc.$392
  • AbbVie$312
  • Johnson & Johnson Vision Care, Inc.$95
  • Alcon$91
  • Tarsus Pharmaceuticals, Inc.$67
  • plus $119 from 6 others

What the payments were for

  • Food & beverage$1,472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,472 in reported general payments places this provider in the 65th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$25,535
Medicare patients
105
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost205$110,014
VyzultaLatanoprostene Bunod82$50,738
RocklatanNetarsudil Mesylat/Latanoprost99$47,273
RestasisCyclosporine27$22,636
Latanoprost584$9,028
SimbrinzaBrinzolamide/Brimonidine Tart23$5,844
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$5,004
Travoprost47$4,112
Brimonidine Tartrate146$1,395
Dorzolamide Hcl69$1,361
Timolol Maleate119$851
Prednisolone Acetate18$643
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$312$132,650232 claims
Bausch & Lomb Americas Inc.Vyzulta$392$50,73882 claims
Aerie Pharmaceuticals, Inc.Rocklatan$396$47,27399 claims
AlconSimbrinza$91$5,84423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →